Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Mantle cell lymphoma is characterized by t(11;14) with fusion and manifests with a spectrum of disease ranging from relatively indolent to aggressive. Here, we present a case of pleomorphic mantle cell lymphoma with three fusion signals that presented with lethal atraumatic splenic rupture. We discuss on the implications of variant CCND1 signal patterns as well as the epidemiology and pathophysiology of atraumatic splenic rupture.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597805 | PMC |
| http://dx.doi.org/10.4322/acr.2021.340 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multifaceted cfDNA profiling in mantle cell lymphoma.
Blood Adv
September 2025
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Mantle Cell Lymphoma with Severe Hyperleukocytosis and Bone Marrow Infiltration.
Clin Lab
September 2025
Background: Mantle cell lymphoma (MCL) is a subtype of non-Hodgkin lymphoma characterized by the proliferation of B-cells. Severe hyperleukocytosis is an uncommon presentation that can complicate the diagnosis and management of MCL.
Methods: We present the case of an 80-year-old male patient suffering from MCL, who exhibited symptoms including severe hyperleukocytosis, lymphadenopathy, and significant bone marrow infiltration.
Ibrutinib-associated hematoma of the liver: role of ultrasound in diagnosis and clinical management.
J Ultrasound
September 2025
Department of Internal Medicine and Medical Therapy, University of Pavia (UniPV), Pavia, Italy.
Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has transformed the management of mantle cell lymphoma (MCL) but is associated with an elevated risk of bleeding. We report a rare case of hepatic subcapsular hematoma due to ibrutinib in a patient with relapsed MCL. Ultrasound was crucial in the early detection, monitoring, and management of this rare but potentially severe complication.
View Article and Find Full Text PDFComposite chronic lymphocytic leukemia and mantle cell lymphoma involving the bone marrow: a case report and literature review.
J Pathol Transl Med
September 2025
Department of Pathology and Laboratory Medicine, University of California, Irvine (UCI), Irvine, CA, USA.
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a clinically indolent lymphoproliferative disorder characterized by accumulation of mature B-cell lymphocytes. Given the common CD5 co-expression, mantle cell lymphoma (MCL) is one of the most important entities in the differential diagnosis. MCL and CLL/SLL might exhibit overlapping morphologic and immunohistochemical features, making diagnosis particularly difficult in cases of composite lymphomas.
View Article and Find Full Text PDFDisease management landscape in patients with mantle cell lymphoma in Japan: a real-world study.
Future Oncol
September 2025
Eli Lilly and Company, Indianapolis, IN, USA.
Aim: The objective of this study was to describe the disease management landscape for patients with mantle cell lymphoma (MCL) in Japan.
Methods: We conducted a cross-sectional survey with retrospective data capture of physicians and their consulting patients between March and December 2022. Physicians completed patient record forms in a 1:2 ratio: one patient receiving first-line (1 L) treatment and two patients with relapsed/refractory disease, one of whom must have received and discontinued a Bruton's tyrosine kinase inhibitor (BTKi).